| 货号 | AF1886-SP |
| 别名 | B cell stimulatory factor-2; B-cell differentiation factor; BSF-2; BSF2CTL differentiation factor; CDF; HGFHSFIFNB2Hybridoma growth factor; IFN-beta 2; IFN-beta-2; IL-6B-cell stimulatory factor 2; Interferon beta-2; interleukin 6 (interferon, beta 2); interleukin BSF-2; interleukin-6; MGI-2A | 全称 | Interleukin 6 |
| 反应种属 | Equine |
| 应用 | Western Blot(0.1 µg/mL) Immunocytochemistry(5-15 µg/mL) |
| 目标/特异性 | Detects equine IL‑6 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 50% cross-reactivity with recombinant human IL-6, recombinant porcine IL-6 and recombinant canine IL-6 is observed and approximately 20% cross-reactivity with recombinant mouse IL-6 and recombinant rat IL-6 is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Immunocytochemistry: 5-15 µg/mL Neutralization: Measured by its ability to neutralize IL‑6-induced proliferation in the T1165.85.2.1 mouse plasmacytoma cell line. Nordan, R. P. and M. Potter (1986) Science 233:566. The Neutralization Dose (ND50) is typically 0.5-1.5 µg/mL in the presence of 4 ng/mL Recombinant Equine IL‑6. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 3569 (Human); 16193 (Mouse); 24498 (Rat); 399500 (Porcine); 280826 (Bovine); 403985 (Canine); 100034196 (Equine); 493687 (Feline); 100008733 (Rabbit) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Serum interleukin-6 (IL-6) and IL-10 concentrations in normal and septic neonatal foals. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | E. coli-derived recombinant equine IL‑6 Phe26-Met208 Accession # Q95181 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Equine |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Interleukin 6 (IL-6) is a pleiotropic alpha -helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is central to the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22 kDa‑28 kDa phosphorylated and variably glycosylated molecule (1‑4). Mature equine IL-6 is 181 amino acids (aa) in length and shares 61%, 42%, and 43% aa sequence identity with human, mouse, and rat IL-6 (5). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization (6). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (7). Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage (3). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130-expressing cells that lack cell surface IL‑6 R (3). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous while that of IL-6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes (3). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor (4, 8). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
Cell Proliferation Induced by IL‑6 and Neutralization by Equine IL‑6 Antibody. Recombinant Equine IL‑6 (Catalog # 1886-EL) stimulates proliferation in the T1165.85.2.1 mouse plasmacytoma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Equine IL‑6 (4 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Equine IL‑6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1886). The ND50 is typically 0.5‑1.5 µg/mL. | |
IL‑6 in Equine PBMCs. IL‑6 was detected in immersion fixed equine peripheral blood mononuclear cells (PBMCs) using Goat Anti-Equine IL‑6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1886) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to the cell surface. View our protocol for Fluorescent ICC Staining of Non-adherent Cells. |
